Showing results (351-360 of 5,925) with videos related to

Sort By:
Pageof 593
The Prostate|April 20, 2018
Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancerHamid Bayat, Behzad Narouie, Seyed-Amir Mohsen Ziaee, et al.
The Prostate|January 1, 1988
5 alpha-reductase activity in epithelium and stroma of prostates from intact and castrated dogs treated with androstenedione, the aromatase inhibitor 1-methyl-1,4-androstadiene-3,17-dione, and cyproterone acetateS Tunn, H Hochstrate, U F Habenicht, et al.
The Prostate|October 11, 2021
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapyMasaya Jimbo, Jack R Andrews, Mohamed E Ahmed, et al.
The Prostate|October 11, 2021
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapyLiam Widjaja, Thorsten Derlin, Tobias L Ross, et al.
The Prostate|October 25, 2021
Long-term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrenceMatteo Droghetti, Angelo Porreca, Lorenzo Bianchi, et al.
The Prostate|September 23, 2021
Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathwayDaoquan Liu, Jianmin Liu, Yan Li, et al.
The Prostate|September 30, 2021
Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysisChaowen Yu, Lingfang Niu, Luo Li, et al.
The Prostate|July 19, 2022
The 28th Annual Prostate Cancer Foundation Scientific Retreat reportAndrea K Miyahira, Howard R Soule
The Prostate|January 1, 1987
Echogenic structure of prostatic cancer imaged on radical prostatectomy specimensJ O Salo, S Rannikko, J Mäkinen, et al.
The Prostate|April 18, 2022
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimensKobe C Yuen, Ben Tran, Angelyn Anton, et al.
Pageof 593